Publications

Diabetes and clinical outcome in patients with metastatic colorectal cancer: CALGB 80405 (Alliance)

JC Brown, S Zhang, FS Ou, AP Venook, D Niedzwiecki, HJ Lenz, ...

Duration of therapy for locally advanced pancreatic cancer: Does it matter?

Tuli R, David J, Lobaugh S, Zhang Z, O'Reilly EM

Early progression (progr) in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) versus placebo (P).

T Macarulla, HL Kindler, P Hammel, M Reni, E Van Cutsem, MJ Hall, ...

Early progression in patients (pts) with metastatic pancreatic cancer (mPaC) and a germline BRCA mutation (gBRCAm): Phase III POLO trial of olaparib (O) vs placebo (P)

A Reinacher-Schick, T Macarulla, HL Kindler, P Hammel, M Reni, ...

Effect of video-based patient education on pancreatic cancer knowledge and behavior.

W Turell, T Ackbarali, EM O'Reilly, M Alsante, K Pucci, EA Del Nido

Enhanced specificity of high sensitivity somatic variant profiling in cell-free DNA via paired normal sequencing: design, validation, and clinical experience of the MSK-ACCESS …

AR Brannon, G Jayakumaran, M Diosdado, J Patel, A Razumova, Y Hu, ...

Étude de phase II «basket» évaluant l’efficacité de l’anticorps monoclonal bispécifique anti-HER2/HER3 MCLA-128 chez les patients atteints de tumeurs solides avancées …

AM Schram, A Drilon, T Macarulla, EM O’Reilly, J Rodon, B Wolpin, ...

Evolutionary dynamics of non-coding regions in pancreatic ductal adenocarcinoma

A Hayashi, Y Ho, AP Makohon-Moore, A Zucker, J Hong, JG Reiter, ...

Extracellular vesicle and particle biomarkers define multiple human cancers

A Hoshino, HS Kim, L Bojmar, KE Gyan, M Cioffi, J Hernandez, ...

Genetic algorithms to identify homologous recombination deficiency (HRD) in pancreas adenocarcinoma

W Park, J Chen, JF Chou, C Iacobuzio-Donague, N Riaz, EM O'Reilly

Genetic and clinical correlates of entosis in pancreatic ductal adenocarcinoma

Hayashi A, Yavas A, McIntyre CA, Ho YJ, Erakky A, Wong W, Varghese AM, Melchor JP, et al.

Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection

Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, …

Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings

Maynard H, Stadler ZK, Berger MF, Solit DB, Ly M, Lowery MA, Mandelker D, Zhang L, et al.

Germline mutation prevalence in young adults with cancer

ZK Stadler, A Maio, A Padunan, Y Kemel, E Salo-Mullen, M Sheehan, ...

Impact of prior irinotecan exposure on outcomes of metastatic pancreatic cancer (mPC) patients.

EM O'Reilly, A Surinach, A Dillon, P Cockrum, KH Yu

Landscape of DNA-damage-repair/homologous recombination deficiency (DDR/HRD) in hepatopancreaticobiliary (HPB) cancers.

W Park, E Sokol, J Chen, KH Yu, D Khalil, JJ Harding, IH El Dika, N Riaz, ...

Large-Cell Neuroendocrine Carcinoma of the Lung: A Population-Based Study

Kinslow CJ, May MS, Saqi A, Shu CA, Chaudhary KR, Wang TJC, Cheng SK

Liver and bile duct cancer

GK Abou-Alfa, W Jarnagin, I El Dika, M D'Angelica, M Lowery, K Brown, ...

Metastatic pancreatic cancer: ASCO guideline update

DPS Sohal, EB Kennedy, P Cinar, T Conroy, MS Copur, CH Crane, ...

Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver

El Dika I, Bowman AS, Berger MF, Capanu M, Chou JF, Benayed R, Zehir A, Shia J, et al.

NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+ 5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in …

A Dean, ZA Wainberg, TS Bekaii-Saab, R Hubner, T Macarulla, ...

NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+ 5-fluorouracil/leucovorin+ oxaliplatin versus nab-paclitaxel+ gemcitabine in patients …

ZA Wainberg, TS Bekaii-Saab, R Hubner, T Macarulla, AS Paulson, ...

Neoadjuvant or adjuvant therapy for resectable or borderline resectable pancreatic cancer: which is preferred?

EM O’Reilly, C Ferrone

Neoadjuvant treatment in patients with resectable and borderline resectable pancreatic cancer

QP Janssen, EM O'Reilly, CHJ Van Eijck, B Groot Koerkamp

New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma

Singh RR, O'Reilly EM

Nutrition and physical activity professional education in gastrointestinal oncology: a national multidisciplinary survey

Hilmi M, Pellat A, Benoit O, Foucaut AM, Mino JC, Kauffmann A, Rochet F, Heuze E, et al.

Oral squamous cell carcinoma as a complication of treatment for recurrent high‐grade serous cancer

LE Moses, JM Rotsides, FO Balogun, MS Persky, FM Muggia, MJ Persky

Outcomes associated with immune-related adverse events in metastatic non-small cell lung cancer treated with nivolumab: a pooled exploratory analysis from a global cohort

Naqash AR, Ricciuti B, Owen DH, Florou V, Toi Y, Cherry C, Hafiz M, … Park W, …

P854 Construction of the immune landscape of durable response to checkpoint blockade therapy by integrating publicly available datasets

NP Rudqvist, R Zappasodi, D Wells, V Thorsson, A Cogdill, A Monette, ...

Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline BRCA mutation …

MJ Hall, T Golan, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

Pancreatic cancer (PaC)-specific health-related quality of life (HRQoL) with maintenance olaparib (O) in patients (pts) with metastatic (m) PaC and a germline</i> BRCA<//i …

D Arnold, MJ Hall, T Golan, P Hammel, M Reni, E Van Cutsem, ...

Pancreatic ductal adenocarcinoma (PDAC), BRCA: Detailed analysis and outcomes of cohort from Memorial Sloan Kettering Cancer Center (MSK).

P Momtaz, CA O'Connor, JF Chou, M Capanu, KH Yu, AM Varghese, ...

PD-1 blockade in advanced adrenocortical carcinoma

N Raj, Y Zheng, V Kelly, SS Katz, J Chou, RKG Do, M Capanu, D Zamarin, ...

Pharmacogenomic blood-based assay to predict chemotherapy response and survival in pancreatic cancer.

KH Yu, B McCarthy, WH Isacoff, B Cooper, A Bartlett, J Park, F Purcell, ...

Phase 1b study of a small molecule antagonist of human chemokine (CC motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of …

M Noel, EM O’Reilly, BM Wolpin, DP Ryan, AJ Bullock, CD Britten, ...

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo)+ BL-8040 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric …

DY Oh, JA Ajani, YJ Bang, HC Chung, J Lacy, J Lee, T Macarulla, ...

Phase Ib/II open-label, randomized evaluation of 2L atezolizumab (atezo)+ PEGPH20 versus control in MORPHEUS-pancreatic ductal adenocarcinoma (M-PDAC) and MORPHEUS-gastric …

AH Ko, J Lee, M ALSINA, JA Ajani, YJ Bang, HC Chung, J Lacy, ...

Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib

El Dika I, Capanu M, Chou JF, Harding JJ, Ly M, Hrabovsky AD, Do RKG, Shia J, et al.

Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC).

W Park, EM O'Reilly, J Furuse, F Kunieda, F Jie, HL Kindler

Phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + Gem) versus gemcitabine (Gem) alone for patients with resected pancreatic cancer (PC …

M Reni, H Riess, EM O'Reilly, JO Park, H Hatoum, BL Saez, T Salminen, ...

Phase III, international, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P + G) versus gemcitabine (G) for resected pancreatic cancer (APACT …

V Sahai, J Tabernero, E Van Cutsem, M Reni, MA Tempero, EM O'Reilly, ...

POLO: Efficacy and Health-Related Quality of Life (HRQOL) with Maintenance Olaparib Following First-Line Platinum-Based Chemotherapy (PBC) in Patients (PTS) with a Germline …

AC Reinacher-Schick, HL Kindler, P Hammel, M Reni, E Van Cutsem, ...

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).

LH Schwartz, HL Kindler, P Hammel, M Reni, E Van Cutsem, T Macarulla, ...

Professional and Psychological Impacts of the COVID-19 Pandemic on Oncology Residents: A National Survey

Hilmi M, Boilève A, Ducousso A, Michalet M, Turpin A, Neuzillet C, Naoun N

Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma

EM O'Reilly, D Barone, D Mahalingam, T Bekaii-Saab, SH Shao, J Wolf, ...

Randomized phase II trial of pazopanib versus placebo in patients (Pts) with progressive carcinoid tumors (CARC)(Alliance A021202)

E Bergsland, M Mahoney, T Asmis, N Hal, P Kumthekar, M Maitland, ...

Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA/PALB2 mutation

EM O’Reilly, JW Lee, M Zalupski, M Capanu, J Park, T Golan, E Tahover, ...

Real-world patterns of care among patients with metastatic pancreatic cancer (mPC).

EM O'Reilly, A Surinach, Z Wu, P Cockrum

Reducing nihilism in metastatic pancreatic ductal adenocarcinoma: Treatment, sequencing, and effects on survival outcomes

O'Reilly EM, Cockrum P, Surinach A, Wu Z, Dillon A, Yu KH

Reply to GW Peters et al and S. Shi et al

EM O'Reilly, C Ferrone